| Issue | Title | |
| Vol 2006, No 71 (2006) | Ranbaxy on Acquisition Spree | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 71 (2006) | Ranexa (ranolozaine) | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 53 (2004) | Raptiva (efalizumab) | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 3 (2010) | Ratiopharm Acquisition Catapults Teva to Lead European Generics Market | Abstract |
| PharmaDeals Analyst | ||
| Vol 2006, No 72 (2006) | Ready Steady Bio | Details jpg |
| Business Review Editor | ||
| Vol 2012, No 1 (2012) | Reata Pharmaceuticals Partners Again with Abbott for US$400 M Upfront | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 65 (2005) | Reckitt Beats GSK to Boots | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 2 (2013) | Reckitt Benckiser Licenses Seven OTC Brands from BMS in Latin America | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 1 (2011) | Reckitt Benckiser to Acquire India’s Paras Pharmaceuticals for US$725 M | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 12 (2012) | Reckitt Benckiser Ventures into Vitamins, Minerals and Supplements Market with Schiff Nutrition Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 91 (2008) | Reckitt Goes to the US with Adams | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 101 (2008) | Recordati Enters Turkey with the Acquisition of Yeni Ilac | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2005, No 55 (2005) | Recordati SpA | Abstract pdf |
| Business Review Editor | ||
| Vol 2024, No 10 (2024) | Recordati to Acquire Sanofi’s Rare Disease Antibody Drug Enjaymo for US$825 M Upfront | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2003, No 35 (2003) | Regeneron and Novartis to Develop Rheumatoid Arthritis Treatment | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 4 (2022) | Regeneron Bolsters I-O Portfolio with US$250 M Checkmate Acquisition | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2023, No 9 (2023) | Regeneron Buys Partner Decibel Therapeutics for Up to US$213 M | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2022, No 11 (2022) | Regeneron Collaborates with CytomX in Bispecific Cancer Deal | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2018, No 8 (2018) | Regeneron Forges a US$100 M Oncology Partnership with Bluebird Bio | Abstract pdf html |
| Michelle Liu | ||
| Vol 2019, No 4 (2019) | Regeneron Forms Second RNAi Partnership with Alnylam | Abstract pdf html |
| Michelle Liu | ||
| Vol 2014, No 6 (2014) | Regeneron Looks to Avalanche’s Ocular BioFactory™ for Potential Eylea® Successor | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 91 (2008) | Regeneron’s Share Price Soars as New Deal with sanofi-aventis is Signed | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 8 (2012) | Regulus Therapeutics Adds Biogen Idec to its List of Partners with miRNA Biomarker Deal | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 94 (2008) | Regulus' microRNA Proves Attractive to GSK | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2008, No 94 (2008) | Removals | Details jpg |
| Business Review Editor | ||
| Vol 2005, No 61 (2005) | Renovis and Pfizer Enter Substantial Agreement | Abstract |
| Business Review Editor | ||
| Vol 2011, No 11 (2011) | Repligen Agrees to Buy Novozymes Biopharma Sweden to Increase its Revenue Potential | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 3 (2013) | Resolve Therapeutics Secures Path to Liquidity via Option Deal with Takeda | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 7 (2011) | Rib-X Pharmaceuticals Signs Global Antibiotic Research Collaboration with Sanofi | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 57 (2005) | Risk and Reward | Details html |
| Fintan Walton | ||
| Vol 2006, No 71 (2006) | Risk, Cost and Reward | Abstract html |
| Fintan Walton | ||
| Vol 2008, No 94 (2008) | Roche - Still One Step Ahead? | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 39 (2003) | Roche Acquires Cardion’s IL-15 Antagonist | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 83 (2007) | Roche Acquires Exclusive Licence for Clinical Phase Cancer Vaccine | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 9 (2022) | Roche Acquires Good Therapeutics for US$250 M Upfront | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2018, No 2 (2018) | Roche Acquires Oncology Data Specialist Flatiron in US$1.9 B Deal | Abstract pdf html |
| Jawala Prasad | ||
| Vol 2019, No 11 (2019) | Roche Acquires Promedior for Up to US$1.4 B | Abstract pdf html |
| Michelle Liu | ||
| Vol 2018, No 10 (2018) | Roche Acquires Tusk Therapeutics for its Regulatory T Cell Research in Oncology | Abstract pdf html |
| Michelle Liu | ||
| Vol 2019, No 3 (2019) | Roche Advances Gene Therapy Investment with Spark Acquisition | Abstract pdf html |
| Michelle Liu | ||
| Vol 2021, No 4 (2021) | Roche Advances Infectious Disease Diagnostic Portfolio with US$1.8 B GenMark Acquisition | Abstract pdf html |
| Debadrita Paul & Michelle Liu | ||
| Vol 2007, No 86 (2007) | Roche and AstraZeneca Join the RNAi Race | Abstract pdf |
| Business Review Editor | ||
| Vol 2020, No 7 (2020) | Roche and Blueprint Medicines Partner Again in US$1.7 B Pralsetinib Pact | Abstract pdf html |
| Neha Madhwani & Michelle Liu | ||
| Vol 2003, No 35 (2003) | Roche and Epigenomics Enter Cancer Diagnostics R&D Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 1 (2010) | Roche and Galapagos in COPD Alliance | Abstract |
| Taskin Ahmed | ||
| Vol 2018, No 10 (2018) | Roche and Ionis Enter into Eye Disease Collaboration | Abstract pdf html |
| Michelle Liu | ||
| Vol 2002, No 29 (2002) | Roche and Kosan to Co-develop Anticancer Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 54 (2004) | Roche and Pharmasset Join Forces in Hepatitis C | Abstract |
| Business Review Editor | ||
| Vol 2012, No 7 (2012) | Roche and Seaside Therapeutics Collaborate to Develop Disease-Modifying Therapies for Neurodevelopmental Disorders | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 83 (2007) | Roche and Synosia: Spinning Out a Future | Abstract pdf |
| Business Review Editor | ||
| Vol 2024, No 1 (2024) | Roche Bolsters Pipeline with MediLink, Remix and MOMA Therapeutics Collaborations | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2022, No 8 (2022) | Roche Bolsters Pipeline with Poseida and Kiniksa Deals | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2011, No 7 (2011) | Roche Broadens its Cancer Diagnostics Portfolio with mtm laboratories Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 8 (2010) | Roche Collaborates with Aileron to Develop Stapled Peptide Therapeutics | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 51 (2004) | Roche Consumer Health Sold to Bayer | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 47 (2004) | Roche Endorses ArQule’s Oncology Platform with US$276 M Alliance | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 10 (2018) | Roche Expands Cell Therapy Collaboration with SQZ Biotech | Abstract pdf html |
| Michelle Liu | ||
| Vol 2011, No 11 (2011) | Roche Expands its HCV Pipeline with Anadys Pharmaceuticals Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 12 (2101) | Roche Forays in Rare Diseases by Licensing PTC Therapeutics’ Spinal Muscular Atrophy Programme | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 97 (2008) | Roche Gains Novel Anticancer Antibody Product | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2009, No 3 (2009) | Roche Gets Genentech for US$46.8 B | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 1 (2009) | Roche Gets Hostile with Genentech | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2018, No 1 (2018) | Roche Hands Over US$1.7 B for Ignyta Buyout | Abstract pdf html |
| Natasha Piper | ||
| Vol 2020, No 1 (2020) | Roche In-licenses Amunix’s Half-life Extension Technology in US$1.5 B Deal | Abstract html pdf |
| Sharath Chandra Nakka | ||
| Vol 2012, No 10 (2012) | Roche In-Licenses Galaxy Biotech’s Preclinical FGF2 Antibody Programme | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 77 (2006) | Roche is Actively Enhancing its Pipeline | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 27 (2002) | Roche Licenses Alzheimer’s Compounds from Memory Pharmaceuticals | Abstract |
| Business Review Editor | ||
| Vol 2011, No 9 (2011) | Roche Licenses Alzheimer’s Disease Drug Candidate from Evotec in Potential US$830 M Deal | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 2 (2013) | Roche Licenses Chiasma’s Late-Stage Oral Acromegaly Therapy | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 12 (2019) | Roche Licenses Sarepta’s DMD Therapy for US$2.88 B | Abstract pdf html |
| Michelle Liu | ||
| Vol 2013, No 9 (2013) | Roche Looks to Combination Immunotherapies with Inovio DNA Vaccine Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 10 (2023) | Roche Partners with Ionis for RNA-Targeting Neurology Programmes | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2014, No 5 (2014) | Roche Partners with Oryzon Genomics and Spero Therapeutics | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 10 (2017) | Roche Partners with Warp Drive Bio in Search of New Antibiotic Classes | Abstract pdf html |
| Natasha Piper | ||
| Vol 2023, No 10 (2023) | Roche Pays US$7.1 B for Bowel Disease Drug from Roivant and Pfizer | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2025, No 3 (2025) | Roche Pays Zealand Pharma US$1.65 B Upfront for Obesity Drug Petrelintide | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2004, No 43 (2004) | Roche Reinvigorates Anti-Infective Franchise with Sankyo’s Antibiotic | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 31 (2002) | Roche Secured Option on Antisoma Pipeline | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 98 (2008) | Roche Seizes its Chance to Buy Genentech | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2013, No 4 (2013) | Roche Sharpens its Focus on Chinese HCV Market with Ascletis Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 11 (2013) | Roche Signals Return to Antibiotics Development with Polyphor Licensing Deal | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 41 (2003) | Roche Signs Collaborative Deals with BioFocus and ParAllele | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 42 (2003) | Roche Signs Deals with Ipsen and Aspreva | Abstract pdf |
| Business Review Editor | ||
| Vol 2024, No 7 (2024) | Roche Signs US$1.82 B Deal with Ascidian for RNA-Targeting Neurology Programmes | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2023, No 10 (2023) | Roche Signs US$2 B Partnership with Monte Rosa for Molecular Glue Medicines | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2023, No 8 (2023) | Roche Signs US$2.8 B Deal with Alnylam to Develop RNAi Therapeutic for Hypertension | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2010, No 8 (2010) | Roche Strengthens CNS Pipeline with reMYND Alliance | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 77 (2006) | Roche Subsidiary Genentech Enters into Agreement with CGI | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 83 (2007) | Roche to Acquire BioVeris for US$21.50 per share | Abstract pdf |
| Business Review Editor | ||
| Vol 2023, No 12 (2023) | Roche to Acquire Carmot Therapeutics for US$3.1 B | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2024, No 12 (2024) | Roche to Acquire Poseida Therapeutics for US$1.5 B | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2003, No 33 (2003) | Roche to Bid US$1.2 B for Diabetes Firm, Disetronic | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 9 (2014) | Roche to Buy InterMune for US$8.3 B to Gain Pirfenidone for Idiopathic Pulmonary Fibrosis | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 67 (2006) | Roche: Recognising BioCryst's Potential? | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 31 (2002) | Roche’s Option on Antisoma | Abstract |
| Business Review Editor | ||
| Vol 2008, No 92 (2008) | Roche’s Persistence in Face of Ventana’s Opposition Pays Off | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 9 (2017) | Rocket Pharmaceuticals Reverse Merges with Inotek Pharmaceuticals to Advance Gene Therapies | Abstract pdf html |
| Natasha Piper | ||
| Vol 2008, No 92 (2008) | Royal Philips Electronics to Acquire Respironics | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 52 (2004) | Royalty Rates - What is There to Hide? | Details html |
| Fintan Walton | ||
| Vol 2007, No 89 (2007) | Royalty Rates in Pharmaceutical Licensing Deals | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 61 (2005) | Royalty Rates Used in Pharmaceutical Agreements | Abstract pdf |
| Business Review Editor | ||
| 2001 - 2100 of 2581 Items | << < 16 17 18 19 20 21 22 23 24 25 > >> | |